Stockreport

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics, Inc.  (TNYA) 
PDF Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to [Read more]